DelveInsight’s Bipolar Depression market report provides thorough comprehension of Bipolar Depression, historical and forecasted epidemiology, and Bipolar Depression market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).
Key Takeaways from the Bipolar Depression Market Report
According to the National Institute of Mental Health (NIMH), a branch of the National Institutes of Health, the 12-month prevalence of bipolar disorder among US adults aged 18 and older was found to be 2.8% based on diagnostic interview data from the National Comorbidity Survey Replication (NCS-R). It also stated that an estimated 4.4% of adults in the United States have bipolar disorder at some point in their lives.
As per DelveInsight estimates, the total Bipolar Depression diagnosed prevalent cases were 2,401,287 in the US in 2020, which is further expected to increase by 2030.
As per the estimates, the highest Bipolar Depression prevalent cases were of severe cases followed by moderate and mild in the UK in 2020.
The leading pharma companies developing therapies to improve the Bipolar Depression treatment landscape include Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, and others.
Key Bipolar Depression therapies in the pipeline include Caplyta (Lumateperone; ITI-007), NRX-100/NRX-101, Rexulti/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others.
NeuroRx has developed a sequential therapy that consists of intravenous NRX-100 (ketamine HCL) for rapid stabilisation of depression and suicidal ideation, followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilisation from depression and suicidal ideation symptoms.
SEP-4199 (Sunovion) is a non-racemic ratio of amisulpride enantiomers that has the potential to be the first benzamide treatment for mood disorders available in the United States.
The Bipolar Depression market size is anticipated to grow at a CAGR of 11.9% during the study period (2017-30).
Want to learn more? Request for sample @ Bipolar Depression Market Outlook
Bipolar Depression: Overview
Bipolar Disorder (BD) is a mental illness marked by mood swings between depression and mania. BD is classified into four types based on the characteristics of the episodes: BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS).
Bipolar Depression Epidemiology Segmentation
The Bipolar Depression report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Bipolar Depression Total Diagnosed Prevalent Cases
Bipolar Depression Type-Specific Diagnosed Prevalent Cases
Bipolar Depression Severity-Specific Diagnosed Prevalent Cases
Bipolar Depression Total Treated Cases
Bipolar Depression Treatment Landscape
Bipolar Depression treatment’s ultimate goal is to achieve a high level of psychosocial function and health-related quality of life. For bipolar depression patients, several off-label uses of therapies, or combinatorial therapy, are common. Anticonvulsants (such as Divalproex and Lamotrigine), Olanzapine monotherapy, and combined lithium and lamotrigine therapy have all been shown to reduce the severity of depressive symptoms in BD patients. Except for fluoxetine when combined with olanzapine, no antidepressant is explicitly approved by the FDA for bipolar depression treatment.
Antidepressant monotherapy is discouraged in bipolar I disorder, mainly when mixed features are present and even when combined with a mood stabiliser. ECT, repetitive transcranial magnetic stimulation, deep brain stimulation, vagus nerve stimulation, lifestyle interventions, and psychotherapies are examples of non-pharmacological treatments for bipolar depression.
Apart from these, some FDA-approved drugs such as Olanzapine‐fluoxetine combination (OFC), Quetiapine, Lurasidone, and Cariprazine are also used for Bipolar Depression treatment.
Bipolar Depression Market Outlook
The Bipolar Depression market size is anticipated to grow at a CAGR of 11.9% during the study period (2017-30). Furthermore, the Bipolar Depression treatment space will see a significant impact in the coming years as treatment improves over time along with the launch of novel therapies such as Caplyta, NRX-100/NRX-101, SEP-4199, and others.
For more information on the market outlook of bipolar depression, visit Bipolar Depression Market Size
Bipolar Depression Pipeline Therapies and Key Companies
Caplyta (Lumateperone; ITI-007): Intra-Cellular Therapies
NRX-100/NRX-101: NeuroRx
Rexulti/Rxulti (Brexpiprazole): Otsuka/ Lundbeck
SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
COMP 360 (Psilocybin Therapy): COMPASS Pathways
Falkieri (Esketamine DPI): Celon Pharma
Bipolar Depression Market Drivers
Future Directions in Blood Biomarkers
Increase in Awareness and Technology
Advances Toward Precision Medicine for BD
Bipolar Depression Market Barriers
Misdiagnosis of Bipolar Depression
Unsatisfactory Design of RCTs
Limited Understanding of the Disease Mechanism
Scope of the Report
Bipolar Depression Key Companies: Intra-Cellular Therapies, NeuroRx, Otsuka, Lundbeck, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, Celon Pharma, among others.
Bipolar Depression Key Pipeline Therapies: Caplyta (Lumateperone; ITI-007), NRX-100/NRX-101, Rexulti/Rxulti (Brexpiprazole), SEP-4199, COMP 360 (Psilocybin Therapy), Falkieri (Esketamine DPI), and others.
Bipolar Depression Segmentation: By Geography, By Bipolar Depression therapies
Analysis: Comparative and conjoint analysis of Bipolar Depression emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Bipolar Depression Market Overview at a Glance
4.
Executive Summary of Bipolar Depression
5.
Bipolar Depression Epidemiology and Market Methodology
6.
Bipolar Depression Disease Background and Overview
7.
Diagnosis of Bipolar Disorder
8.
Current Treatment Practices of Bipolar Disorder
9.
Bipolar Depression Epidemiology and Patient Population
10.
Bipolar Depression The United States
11.
Bipolar Depression EU-5
12.
Bipolar Depression Japan
13.
Bipolar Depression Patient Journey
14.
Key Endpoints in Bipolar Depression Clinical Trials
15.
Bipolar Depression Marketed Therapies
16.
Bipolar Depression Emerging Therapies
17.
Bipolar Depression: 7 Major Market Analysis
18.
Bipolar Depression The United States Market Size
19.
Bipolar Depression EU-5 Market Size
20.
21.
Bipolar Depression Market Access and Reimbursement
22.
23.
24.
SWOT Analysis
25.
Bipolar Depression Unmet Needs
26.
Appendix
27.
DelveInsight Capabilities
28.
Disclaimer
29.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Major Depressive Disorder Market
Get a comprehensive analysis of Familial Hypercholesterolemia pipeline therapies and key companies such as Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, Fabre-Kramer Pharmaceuticals, SAGE Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/